ESR1 and neoplasm: To further explore the potential effect of having both ER and PgR expressed in more than 50% of tumor cells, we compared the annualized hazards of RFS for cohort A and B patients in the overall, TP50, and no-TP50 (i.e. remainder patients, whose tumor do not have simultaneous expression of ER and PgR in >50% of tumor cells) populations (Figure 2, panels a, b and c, respectively).